Dr. Wanless has over 30 years experience in the pharmaceutical and biotechnology industry and publicly/privately funded clinical research.
Prior to joining Brighton Biotech he served as Vice President (V.P.) of Research and Program Evaluation for the Baylor international Pediatric AIDS Initiative (BIPAI), dedicated to the care and treatment of children with HIV/AIDS in Romania and Africa. He was also appointed as an Associate Professor of Pediatric Retrovirology at Baylor College of Medicine, Houston, Texas. His responsibilities lead him to oversee 61 operational and clinical research studies throughout the BIPAI network and create an innovative M&E framework for the evaluation of the network’s performance. Previously Dr. Wanless served as Senior Medical Director of the Bristol-Myers Squibb (BMS) funded “Secure the Future” program based in Johannesburg, South Africa. During his time as Director he supervised 63 clinical and operational research programs. Prior to his time at “Secure the Future” he spent 17 years at BMS and worked in clinical research, assuming increasing levels of responsibility and international experience in Western Europe, the U.S., Japan and Eastern Europe, ending up as V.P. of Intercontinental Research based in the U.S.
Dr. Wanless qualified in medicine from the University of Edinburgh, Scotland and also holds a BSc. degree in pharmacology and a Ph.D. degree in cardiovascular physiology from the University of London.